In vitro and in vivo characterization of a novel liposomal a butorphanol formulation for treatment of pruritus

Grace J. Lim, Yozo Ishiuji, Aerlyn Dawn, Benjamin Harrison, Do Won Kim, Anthony Atala, Gil Yosipovitch

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

As yet no transdermal topical formulations have been developed for the treatment of chronic itch. We developed a formulation containing 2 mg butorphanol tartrate in 100 μl purified water encapsulated into multilamel-lar phospholipid vesicles. Drug permeation experiments were studied with Franz diffusion chambers using human skin in vitro and on rat skin in vivo. Histological analysis of rat skins was performed to evaluate skin irritation of the formulation in vivo. Physical properties showed stable formulation with desirable viscosity. In vitro dermal penetration rate data suggest that there was significant permeation at time-points 2 h and 4 h, and a steady state was achieved afterwards to 24 h. Maximal plasma butorphanol concentration was noted at 2 h and steady state was achieved at 8 h. Visual skin assessment as well as histological analysis of excised rat skin did not demonstrate any evidence of inflammation and irritation. In vitro and in vivo analysis demonstrated release of a consistent amount of butorphanol in a sustained manner for 24 h. This liposomal transdermal delivery formulation could serve as a method to deliver butorphanol for patients with chronic pruritus.

Original languageEnglish
Pages (from-to)327-330
Number of pages4
JournalActa Dermato-Venereologica
Volume88
Issue number4
DOIs
StatePublished - Jul 28 2008
Externally publishedYes

Fingerprint

Butorphanol
Pruritus
Skin
Therapeutics
In Vitro Techniques
Viscosity
Phospholipids
Inflammation
Water

Keywords

  • Butorphanol
  • Kappa-opioid
  • Liposome
  • Pruritus
  • Transdermal delivery

ASJC Scopus subject areas

  • Dermatology

Cite this

In vitro and in vivo characterization of a novel liposomal a butorphanol formulation for treatment of pruritus. / Lim, Grace J.; Ishiuji, Yozo; Dawn, Aerlyn; Harrison, Benjamin; Kim, Do Won; Atala, Anthony; Yosipovitch, Gil.

In: Acta Dermato-Venereologica, Vol. 88, No. 4, 28.07.2008, p. 327-330.

Research output: Contribution to journalArticle

Lim, Grace J. ; Ishiuji, Yozo ; Dawn, Aerlyn ; Harrison, Benjamin ; Kim, Do Won ; Atala, Anthony ; Yosipovitch, Gil. / In vitro and in vivo characterization of a novel liposomal a butorphanol formulation for treatment of pruritus. In: Acta Dermato-Venereologica. 2008 ; Vol. 88, No. 4. pp. 327-330.
@article{e75f28459a1740a7b66ba24a5e22471d,
title = "In vitro and in vivo characterization of a novel liposomal a butorphanol formulation for treatment of pruritus",
abstract = "As yet no transdermal topical formulations have been developed for the treatment of chronic itch. We developed a formulation containing 2 mg butorphanol tartrate in 100 μl purified water encapsulated into multilamel-lar phospholipid vesicles. Drug permeation experiments were studied with Franz diffusion chambers using human skin in vitro and on rat skin in vivo. Histological analysis of rat skins was performed to evaluate skin irritation of the formulation in vivo. Physical properties showed stable formulation with desirable viscosity. In vitro dermal penetration rate data suggest that there was significant permeation at time-points 2 h and 4 h, and a steady state was achieved afterwards to 24 h. Maximal plasma butorphanol concentration was noted at 2 h and steady state was achieved at 8 h. Visual skin assessment as well as histological analysis of excised rat skin did not demonstrate any evidence of inflammation and irritation. In vitro and in vivo analysis demonstrated release of a consistent amount of butorphanol in a sustained manner for 24 h. This liposomal transdermal delivery formulation could serve as a method to deliver butorphanol for patients with chronic pruritus.",
keywords = "Butorphanol, Kappa-opioid, Liposome, Pruritus, Transdermal delivery",
author = "Lim, {Grace J.} and Yozo Ishiuji and Aerlyn Dawn and Benjamin Harrison and Kim, {Do Won} and Anthony Atala and Gil Yosipovitch",
year = "2008",
month = "7",
day = "28",
doi = "10.2340/00015555-0480",
language = "English",
volume = "88",
pages = "327--330",
journal = "Acta Dermato-Venereologica",
issn = "0001-5555",
publisher = "Society for the Publication of Acta Dermato-Venereologica",
number = "4",

}

TY - JOUR

T1 - In vitro and in vivo characterization of a novel liposomal a butorphanol formulation for treatment of pruritus

AU - Lim, Grace J.

AU - Ishiuji, Yozo

AU - Dawn, Aerlyn

AU - Harrison, Benjamin

AU - Kim, Do Won

AU - Atala, Anthony

AU - Yosipovitch, Gil

PY - 2008/7/28

Y1 - 2008/7/28

N2 - As yet no transdermal topical formulations have been developed for the treatment of chronic itch. We developed a formulation containing 2 mg butorphanol tartrate in 100 μl purified water encapsulated into multilamel-lar phospholipid vesicles. Drug permeation experiments were studied with Franz diffusion chambers using human skin in vitro and on rat skin in vivo. Histological analysis of rat skins was performed to evaluate skin irritation of the formulation in vivo. Physical properties showed stable formulation with desirable viscosity. In vitro dermal penetration rate data suggest that there was significant permeation at time-points 2 h and 4 h, and a steady state was achieved afterwards to 24 h. Maximal plasma butorphanol concentration was noted at 2 h and steady state was achieved at 8 h. Visual skin assessment as well as histological analysis of excised rat skin did not demonstrate any evidence of inflammation and irritation. In vitro and in vivo analysis demonstrated release of a consistent amount of butorphanol in a sustained manner for 24 h. This liposomal transdermal delivery formulation could serve as a method to deliver butorphanol for patients with chronic pruritus.

AB - As yet no transdermal topical formulations have been developed for the treatment of chronic itch. We developed a formulation containing 2 mg butorphanol tartrate in 100 μl purified water encapsulated into multilamel-lar phospholipid vesicles. Drug permeation experiments were studied with Franz diffusion chambers using human skin in vitro and on rat skin in vivo. Histological analysis of rat skins was performed to evaluate skin irritation of the formulation in vivo. Physical properties showed stable formulation with desirable viscosity. In vitro dermal penetration rate data suggest that there was significant permeation at time-points 2 h and 4 h, and a steady state was achieved afterwards to 24 h. Maximal plasma butorphanol concentration was noted at 2 h and steady state was achieved at 8 h. Visual skin assessment as well as histological analysis of excised rat skin did not demonstrate any evidence of inflammation and irritation. In vitro and in vivo analysis demonstrated release of a consistent amount of butorphanol in a sustained manner for 24 h. This liposomal transdermal delivery formulation could serve as a method to deliver butorphanol for patients with chronic pruritus.

KW - Butorphanol

KW - Kappa-opioid

KW - Liposome

KW - Pruritus

KW - Transdermal delivery

UR - http://www.scopus.com/inward/record.url?scp=47749140066&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=47749140066&partnerID=8YFLogxK

U2 - 10.2340/00015555-0480

DO - 10.2340/00015555-0480

M3 - Article

C2 - 18709299

AN - SCOPUS:47749140066

VL - 88

SP - 327

EP - 330

JO - Acta Dermato-Venereologica

JF - Acta Dermato-Venereologica

SN - 0001-5555

IS - 4

ER -